Effects of diflunisal on platelet function and fecal blood loss.
The effects of diflunisal, a nonacetylated difluorinated salicylate, on platelet function were compared with those of aspirin and placebo. In a randomized, double-blind trial, normal subjects were given diflunisal, 250, 500, or 1,000 mg twice daily; aspirin, 650 or 1,300 mg twice daily; or placebo for 8-day periods. Difunisal, 250 mg, had no effect on platelet function, whereas 500 mg induced minimal inhibition of colagen-induced release of platelet serotonin, and 1,000 mg inhibited platelet malondialdehyde production, moderately prolonged template bleeding times (P = NS), and increased fecal blood loss (P less than 0.05). In contrast, aspirin, 650 mg, markedly inhibited collagen-induced platelet aggregation and serotonin release, and 1,300 mg prolonged bleeding time (P less than 0.01) and increased fecal blood loss (P less than 0.01). The effects of aspirin lasted for up to 5 days, whereas changes induced by diflunisal had returned to baseline 24 hr after the drug was discontinued. We conclude that in doses in the same range as those of aspirin diflunisal inhibits platelet function less.
D000328:Adult; D001241:Aspirin / Q000494:pharmacology; D001792:Blood Platelets / Q000187:drug effects* / Q000502:physiology; D004061:Diflunisal / Q000494:pharmacology*; D004311:Double-Blind Method; D005243:Feces / Q000378:metabolism*; D005260:Female; D006471:Gastrointestinal Hemorrhage / Q000378:metabolism*; D006801:Humans; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D010919:Placebos; D010974:Platelet Aggregation / Q000187:drug effects; D010979:Platelet Function Tests; D011897:Random Allocation; D012459:Salicylates / Q000494:pharmacology*; D013997:Time Factors
D010919:Placebos; D012459:Salicylates; D008315:Malondialdehyde; D004061:Diflunisal; D001241:Aspirin